Syn2bio Spolka Akcyjna
GGPW:S2B59.50
PLN
-2.30
(-3.72%)
ISIN
PLSNBIO00013
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
PLN
•
in mil. unless spec.Working Capital
PLN
•
in mil. unless spec.Growth Rates
PLN
•
in mil. unless spec.Quarterly Revenue
PLN
•
in mil. unless spec.Quarterly Earnings Per Share
PLN
•
in mil. unless spec.Quarterly Dividends Per Share
PLN
•
in mil. unless spec.Company Description
- CEO
- Cezary Dariusz Kozanecki
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Warsaw Poland
- IPO Date
- Apr 15, 2026
- Website
- syn2bio.pl
- Similar Companies
- Business
- Syn2bio Spółka Akcyjna is a Poland-based clinical-stage biotechnology company specializing in the research, development, and commercialization of innovative radiopharmaceuticals and specialized molecular imaging diagnostic solutions. The company operates in the biotechnology and nuclear medicine sectors, focusing on diagnostic cardiology and the detection of cardiovascular disorders through positron emission tomography and computed tomography (PET/CT) technologies. Syn2bio S.A. conducts its scientific programs through its dedicated Center for Research on New Molecules (Centrum Badań nad Nowymi Cząsteczkami) and offers core products and development pipelines comprising: SYN2 (kardioznacznik SYN2), a patented next-generation radiopharmaceutical cardiac tracer engineered for PET/CT myocardial perfusion imaging (MPI) to detect coronary artery disease, evaluate myocardial ischemia, and monitor cardiac tissue viability post-infarction, currently advancing through Phase III clinical trials; proprietary molecular compound research and radiolabeling platform development; preclinical and clinical-stage diagnostic imaging validation; and global pharmaceutical licensing programs providing intellectual property rights, milestone-based technology transfers, and commercial distribution partnerships. Headquartered in Warsaw, Poland, and established in 2025 through the corporate spin-off of the research and development division of Synektik S.A., the company targets global healthcare markets with intellectual property protections spanning Europe, North America, and Asia. In recent major developments, Syn2bio S.A. completed its formal demerger from Synektik S.A. to operate as an independent biotechnology enterprise capable of securing specialized research grants and sector-specific capital; completed its public listing on the Main Market of the Warsaw Stock Exchange (Giełda Papierów Wartościowych w Warszawie) in April 2026 under the ticker symbol S2B via a spin-off share distribution; and advanced its lead SYN2 radiotracer program into multinational Phase III clinical evaluations aimed at securing regulatory marketing authorizations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) alongside ongoing negotiations for global commercial out-licensing agreements.